Category: MedtronicSyndicate content

Report: Medtronic shareholder sues to block Covidien merger

July 24, 2014 by Brad Perriello

A Medtronic shareholder is reportedly looking to block the pending, $43 billion merger with Covidien, arguing that the deal leaves stockowners on the hook for significant tax liabilities.

Report: Medtronic shareholder sues to block Covidien merger

Intersect ENT prices IPO at low end of range

July 24, 2014 by Brad Perriello

Intersect ENT prices its initial public offering at $11 per share, the low end of its predicted range, hoping to raise $55 million when XENT shares hit the NASDAQ exchange today.

Intersect ENT prices IPO at low end of range

Intersect ENT said today that it's shares should hit the NASDAQ exchange at $11 apiece, the low end of the range, for expected proceeds of $55 million.

At that price, Intersect would command a market capitalization of roughly $267 million.

Abbott CEO chides critics of corporate inversions | Medtech Wall Street news for the week of July 21, 2014

July 24, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Abbott CEO defends inversions amid corporate exodus furor; Medtronic fights tax dodging rhetoric in Covidien merger; Allergan cuts 1,500 jobs, faces SEC complaint; A countdown to failure for Valeant's hostile $53B Allergan takeover; GE Healthcare idles for another quarter

Abbott CEO defends inversions amid corporate exodus furor

July 18, 2014 by Arezu Sarvestani

Abbott CEO defends inversions amid corporate exodus furor

Medtronic tallies 175 apps for iPhones and iPads | MassDevice.com On Call

July 24, 2014 by Arezu Sarvestani

Medtech titan Medtronic has developed 175 iOS apps for internal use by its employees, according to Apple.

MassDevice.com On Call

JNJ looks to bolster "subscale" cardiovascular business | The week in medtech M&A

July 23, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Johnson & Johnson eyes acquisitions in cardiovascular, elsewhere; Abbott CEO defends inversions amid corporate exodus furor; Medtronic fights tax dodging rhetoric in Covidien merger; Could Medtronic-Covidien deal get caught in anti-inversion legislation?; Siemens sells clinical microbiology biz to Beckman Coulter

Johnson & Johnson eyes acquisitions in cardiovascular, elsewhere

July 16, 2014 by Brad Perriello

YYmeta

Medtronic-Covidien merger may get caught in anti-inversion legislation | Medtech legal news for the week of July 21, 2014

July 21, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Could Medtronic-Covidien deal get caught in anti-inversion legislation?; Medtronic fights tax dodging rhetoric in Covidien merger; Travelers holds out on BD's $67M coverage claim; Abbott CEO defends inversions amid corporate exodus furor; Steris, Medtrica win legal fees in Cygnus Medical patent spat;

Could Medtronic-Covidien deal get caught in anti-inversion legislation?

July 16, 2014 by Arezu Sarvestani

Could Medtronic-Covidien deal get caught in anti-inversion legislation?

Abbott CEO defends inversions amid corporate exodus furor

July 18, 2014 by Arezu Sarvestani

Abbott chairman & CEO Miles White chides critics of corporate inversions as Capitol Hill mulls legislation to strip tax benefits for companies that shift their headquarters overseas.

Abbott CEO defends inversions amid corporate exodus furor
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp